| Patient characteristics before PSW | Patient characteristics (%) after PSWa | ||||
---|---|---|---|---|---|---|
CCT (n = 79) | Without CCT (n = 167) | Standardized differenceb | CCT | Without CCT | Standardized differenceb | |
Number (%)b or mean (SD)b | Number (%)b or mean (SD)b | |||||
Age (years) | Â | Â | Â | Â | Â | Â |
  ≤ 58 | 42 (53) | 90 (54) | 0.015 | 51 | 51 | ≈ 0 |
  > 58 | 37 (47) | 77 (46) |  | 49 | 49 |  |
Gender | Â | Â | Â | Â | Â | Â |
 Female | 4 (5) | 7 (4) | 0.042 | 5 | 5 | ≈ 0 |
 Male | 75 (95) | 160 (96) |  | 95 | 95 |  |
Residency | Â | Â | Â | Â | Â | Â |
 Non-north | 60 (76) | 119 (71) | 0.107 | 74 | 74 | ≈ 0 |
 North | 19 (24) | 48 (29) |  | 26 | 26 |  |
Comorbidity | Â | Â | Â | Â | Â | Â |
 Without | 69 (87) | 146 (87) | 0.003 | 88 | 88 | ≈ 0 |
 Withc | 10 (13) | 21 (13) |  | 12 | 12 |  |
BMI (kg/m2) | Â | Â | Â | Â | Â | Â |
  ≤ 18.5 | 15 (19) | 36 (22) | 0.064 | 19 | 19 | ≈ 0 |
  > 18.5 | 64 (81) | 131 (78) |  | 81 | 81 |  |
Drinking | Â | Â | Â | Â | Â | Â |
 No | 11 (14) | 22 (13) | 0.022 | 14 | 14 | ≈ 0 |
 Yes | 68 (86) | 145 (87) |  | 86 | 86 |  |
Smoking | Â | Â | Â | Â | Â | Â |
 No | 8 (10) | 20 (12) | 0.059 | 11 | 11 | ≈ 0 |
 Yes | 71 (90) | 147 (88) |  | 89 | 89 |  |
Grade | Â | Â | Â | Â | Â | Â |
 Poorly | 25 (32) | 40 (24) | 0.172 | 31 | 31 | ≈ 0 |
 Well/moderately differentiated | 54 (68) | 127 (76) |  | 69 | 69 |  |
Tumor location | Â | Â | Â | Â | Â | Â |
 Upper | 43 (54) | 65 (39) |  | 50 | 50 |  |
 Middle | 25 (32) | 75 (45) | 0.275 | 35 | 35 | ≈ 0 |
 Lower | 11 (14) | 27 (16) | 0.063 | 15 | 15 | ≈ 0 |
Tumor size (cm) | Â | Â | Â | Â | Â | Â |
  ≤ 5 cm | 34 (43) | 61 (37) | 0.133 | 43 | 43 | ≈ 0 |
  > 5 cm | 45 (57) | 106 (63) |  | 57 | 57 |  |
Clinical T-stage | Â | Â | Â | Â | Â | Â |
 T1–T2 | 7 (9) | 17 (10) | 0.045 | 8 | 8 | ≈ 0 |
 T3–T4 | 72 (91) | 150 (90) |  | 92 | 92 |  |
Clinical N-stage | Â | Â | Â | Â | Â | Â |
 N0 | 7 (9) | 8 (5) | 0.162 | 7 | 7 | ≈ 0 |
 N1–N2 | 72 (91) | 159 (95) |  | 93 | 93 |  |
Clinical stage | Â | Â | Â | Â | Â | Â |
 II | 9 (11) | 14 (8) | 0.101 | 10 | 10 | ≈ 0 |
 III | 70 (89) | 153 (92) |  | 90 | 90 |  |
Reason for no surgery | Â | Â | Â | Â | Â | Â |
 Without contraindication | 75 (95) | 154 (92) | 0.111 | 94 | 94 | ≈ 0 |
 With contraindication | 4 (5) | 13 (8) |  | 6 | 6 |  |
RT modality | Â | Â | Â | Â | Â | Â |
 3DCRT | 7 (9) | 4 (2) | 0.283 | 5 | 5 | ≈ 0 |
 IMRT | 72 (91) | 163 (98) |  | 95 | 95 |  |
Use of PET | Â | Â | Â | Â | Â | Â |
 No | 34 (43) | 42 (25) | 0.384 | 35 | 35 | ≈ 0 |
 Yes | 45 (57) | 125 (75) |  | 65 | 65 |  |
RT break | Â | Â | Â | Â | Â | Â |
  ≤ 1 week | 63 (80) | 125 (75) | 0.117 | 79 | 79 | ≈ 0 |
  > 1 week | 16 (20) | 42 (25) |  | 21 | 21 |  |
RT dose | Â | Â | Â | Â | Â | Â |
 Low | 19 (24) | 54 (32) | 0.185 | 26 | 26 | ≈ 0 |
 High | 60 (76) | 113 (68) |  | 74 | 74 |  |
Induction chemotherapy | Â | Â | Â | Â | Â | Â |
 Without | 74 (94) | 162 (97) | 0.159 | 95 | 95 | ≈ 0 |
 With | 5 (6) | 5 (3) |  | 5 | 5 |  |